Wockhardt gets USFDA QIDP designation for WCK 6777
Advertisement
New Delhi: Drug firm WockhardtNSE 0.09 % on Monday said it has received Qualified Infectious Disease Product (QIDP) designation from the US health regulator for its combination antibiotic, WCK 6777.
The QIDP status is granted to drugs that are effective against a set of multi-drug resistant pathogens identified by the Centre for Disease Control, USA, which have a high degree of unmet need in the treatment of patients infected by such pathogens, Wockhardt said in a filing to the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.